pioglitazone / Generic mfg. - LARVOL DELTA

Efficacy and safety of pioglitazone versus dapagliflozin as an add-on to metformin and alogliptin combination therapy: the EPIDOTE study. (PubMed, Sci Rep) - "Pioglitazone added to metformin and alogliptin significantly improved glycemic control in patients with type 2 diabetes, and was non-inferior to dapagliflozin. This study suggests that pioglitazone could be an effective and safe option for patients with inadequate glycemic control on metformin and DPP4i."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Meta-analysis of clinically available pharmacotherapy of biopsy confirmed metabolic dysfunction associated steatohepatitis (MASH). (PubMed, Diabetes Obes Metab) - "Clinically available medications are beneficial in reversing MASH. Improvements in RSw/oF and RFw/oS were greater at earlier stages of fibrosis. Future analyses of drug effects should include assessments adjusted for baseline study characteristics of Fibrosis Grades and may evaluate whether preventive therapy will have long term benefits if started at earlier stages of MASLD."

Journal • Retrospective data • Fibrosis • Hepatitis C • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease

Disproportionality and time-to-onset analyses of drug-induced weight gain using the Japanese Adverse Drug Event Report database. (PubMed, Drug Discov Ther) - "Pregabalin showed the earliest median onset at 19 days (early failure), followed by olanzapine and risperidone at 1-2 months, pioglitazone at 2 months, and clozapine at 6 months, all classified as random failure types. These findings underscore the need for careful weight monitoring during treatment, particularly early with pregabalin and long-term with clozapine and pioglitazone. Prospective studies are warranted to clarify causal relationships and clinical implications."

Adverse events • Journal • Cardiovascular • CNS Disorders • Genetic Disorders • Metabolic Disorders • Obesity

Metabolic effects of pioglitazone and sodium-glucose cotransporter 2 inhibitors in familial partial lipodystrophy. (PubMed, Acta Diabetol) - "We observed modest metabolic improvements following treatment with pioglitazone and SGLT2 inhibitors in patients with FPLD."

Journal • Lipodystrophy • Metabolic Disorders

Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus (clinicaltrials.gov) - P3 | N=480 | Recruiting | Sponsor: EMS | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2026 ➔ Sep 2027 | Trial primary completion date: Mar 2026 ➔ Jul 2026

Enrollment open • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Targeting adipose remodeling: Synergistic mechanisms of drugs and adipose-derived stem cells in obese type 2 diabetes mellitus. (PubMed, World J Stem Cells) - "Although pharmacological agents such as pioglitazone and metformin are effective in modulating fat distribution and improving metabolic parameters, their roles in adipose tissue remodeling remain insufficiently elucidated...It further discussed the potential synergistic benefits of adipose-derived stem cell-based combination interventions. Finally, the review envisioned future directions for integrating molecularly targeted drugs with cell therapies in the personalized management of metabolic disorders."

Journal • Review • Diabetes • Genetic Disorders • Inflammation • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Pioglitazone plus (-)-epigallocatechin gallate: a novel approach to enhance osteogenic performance in aged bone marrow mesenchymal stem cells. (PubMed, FEBS Open Bio) - "Cultures of aged human bone marrow mesenchymal stem cells (bmMSCs) in alginate scaffolds revealed that pioglitazone and EGCG cooperatively enhanced osteoblastic differentiation, biological apatite production, and bone-like tissue maturation. These findings demonstrate that the combination of pioglitazone and EGCG is a promising strategy to enhance osteogenic performance in aged bmMSCs for the development of advanced bone graft materials."

Journal • FASN

Pioglitazone modulates metabolic adaptation and peripheral nerve regeneration after injury. (PubMed, Mol Neurodegener) - "In addition, delayed application of PIO induced lipid metabolism, glycolysis and ATP production in SCs, leading to the assumption that improved metabolic conditions mediate enhanced nerve regeneration in this treatment paradigm. These findings show that depending on the timing of PIO treatment, PPARɣ can serve as a potential therapeutic agent to improve nerve regeneration by promoting key metabolic adaptations."

Journal • Inflammation • Metabolic Disorders

The ameliorative effect of pioglitazone and/or cod liver oil on hepatotoxicity induced by carbon tetrachloride in rats. (PubMed, Genes Nutr) - No abstract available

Journal • Preclinical

Electroacupuncture modulates myocardial insulin signaling and inflammatory markers in a rat model of type 2 diabetes. (PubMed, Acupunct Med) - "EA ameliorated myocardial IR in a rat model of T2DM and positively impacted TNNT2 and BNP levels, as well as phosphorylation status and mRNA expression of several genes involved in the insulin signaling pathway. Our findings underscore the potential of EA to modulate multiple therapeutic targets in the treatment of myocardial IR. If these effects can be replicated clinically, EA may represent a promising non-pharmacological option for the management of cardiometabolic risks associated with diabetes."

Journal • Preclinical • Diabetes • Endocrine Disorders • Metabolic Disorders • Oncology • Type 2 Diabetes Mellitus • AMPK • CRP • IL6 • SLC2A4 • TNFA

Low dose pioglitazone (7.5 mg) provides efficacious glycemic control in Asian Indian patients with poorly controlled diabetes compared to 15 mg: A pilot randomized controlled parallel-group open-label trial over 12 months. (PubMed, Diabetes Metab Syndr) - "Pioglitazone 7.5 mg is an effective and well-tolerated alternative to 15 mg in Asian Indian patients with type 2 diabetes."

Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Type 2 Diabetes Mellitus

Pioglitazone-Based Combination Approaches for Non-Small-Cell Lung Cancer. (PubMed, Pharmaceutics) - "We logically discuss the experimental evidence from the in vitro and in vivo studies exploring pioglitazone's effect on metabolic pathways, chemical-carcinogen-induced tumorigenesis, the targeting of cell signaling pathways, and then its combination with other therapeutic agents. We also present clinical studies that support pioglitazone's potential in chemoprevention and underscore its further exploration in large cohorts of NSCLC patients."

Journal • Review • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Improvement of Liver Fibrosis in Patients with MASLD Undergoing Pioglitazone Treatment: An Update. (PubMed, Life (Basel)) - "This review examines recent epidemiological trends in MASLD and MASH, outlines the mechanisms of action of pioglitazone with an emphasis on its role in improving liver fibrosis, and summarizes clinical studies on fibrosis evaluation during pioglitazone treatment. The literature search focused on English-language studies from the past two years in the PubMed database."

Journal • Review • Diabetes • Fibrosis • Hepatocellular Cancer • Hepatology • Immunology • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Oncology • Solid Tumor • Type 2 Diabetes Mellitus

Repurposed Drugs for Heterotopic Ossification Management: Revitalizing Therapeutic Strategies. (PubMed, Pharmaceuticals (Basel)) - " We performed docking experiments between peroxisome proliferator-activated receptor-γ and bone metabolism-affecting drugs, namely, thiazolidinediones (rosiglitazone, pioglitazone), indomethacin, and dexamethasone, to test tritherapy antiosteoblastogenic effect. These results were consistent with bone turnover modification observed in a congenital HO patient. This concordance underscores tritherapy potential for rapid and safe translation to prevent HO."

Journal • FABP4 • SPP1

HDM and mannose as novel tolerogenic inducers for dendritic cells: mTOR/PPARγ-mediated attenuation of allergic asthma. (PubMed, Eur J Med Res) - "Inhibition of mTOR disrupted this axis and reversed the tolerogenic state, while pharmacological activation of PPARγ with pioglitazone mitigated asthma pathology in vivo. In conclusion, our work establishes HDM and mannose as novel tolerogenic inducers, providing a new strategy for the immunotherapy of asthma."

Journal • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • CD4 • CD80 • CD86 • FOXP3 • PPARG • TNFSF4

Peroxisome proliferator-activated receptors as novel targets of small cell lung cancer circulating tumor cells. (PubMed, Neoplasma) - "Cytotoxicity varied by compound, while the PPARγ agonist pioglitazone and the PPARα agonist fenofibrate were preferentially active in CTC lines, DG172 hydrochloride was selective for pleural effusion-derived lines, while rosiglitazone maleate, cloxiquine, and agrimol B showed no selectivity. These findings support PPARs as clinically relevant targets in SCLC, with PPAR-directed agents showing cytotoxic effects comparable to those reported in other malignancies. Such agents may aid SCLC treatment and help delineate biological differences between CTCs and resident tumor cells."

Circulating tumor cells • Journal • Lung Cancer • Oncology • Respiratory Diseases • Small Cell Lung Cancer • Solid Tumor • BCL2 • BCL2L1 • CASP3 • CASP9 • CFLAR • CTCs • CXCR4 • ICAM1 • PPARA

Cyproterone acetate for hirsutism. (PubMed, Cochrane Database Syst Rev) - "There were some differences in clinical outcome between CPA and spironolactone, CPA and flutamide, and CPA and finasteride. There were no clinical differences between CPA and the other medical therapies, possibly because of small study size, lack of standardised assessment and objective determinants of improvement in many studies. There are insufficient data presented to compare the adverse effects of all the treatment options. Larger, carefully designed studies are needed to compare efficacy and safety profiles between the therapeutic options available."

Clinical • Journal • Review • Gynecology

A Drug Repurposing Strategy for a New Cause of Endometrial Infertility: Unveiling Promising New Treatments. (PubMed, medRxiv) - "This is the first application of a systems-based drug repurposing strategy in IVF to develop tailored therapeutic interventions. We propose genistein, pioglitazone, alprostadil, flunisolide, and tenoxicam as approved, safe drugs identified through an evidence-based approach that could prevent loss of good-quality embryos and miscarriage due to maternal endometrial factors. These findings, supported by functional in vitro validation, pave the way for future clinical trials advancing personalised medicine in endometrial-factor infertility."

Journal • Gynecology • Infertility • Sexual Disorders

Development of a Human Preclinical Platform for the Identification of Neuroprotective Compounds. (PubMed, Eur J Neurosci) - "We demonstrated that pioglitazone and minocycline protected against glutamate-induced axonal injury, rotenone-induced neuronal death and promoted oligodendrocyte differentiation. In summary, our findings demonstrate that human preclinical IPSC platforms can be used to characterize the neuroprotective properties of compounds and thus may aid the selection of drugs for clinical trials. Moreover, the platform's flexibility allows for the easy incorporation of additional disease-specific phenotypic assays."

Journal • Preclinical • CNS Disorders • Inflammation • Multiple Sclerosis • Solid Tumor • GSK3B

Evaluating Pioglitazone for Managing Type 2 Diabetes Mellitus in Patients with Nonalcoholic Fatty Liver Disease. (PubMed, J Assoc Physicians India) - "In T2DM patients with NAFLD, pioglitazone improves glycemic control and reduces both fatty liver grades and fibrosis stages."

Journal • Observational data • Retrospective data • Diabetes • Fibrosis • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Type 2 Diabetes Mellitus

Effect of Oral Hypoglycaemic Agents on Carotid Artery Intima-Media Thickness in Patients With Cardiovascular Disease and/or Diabetes-A Systematic Review. (PubMed, Endocrinol Diabetes Metab) - "The study suggests that prolonged use of Pioglitazone, Repaglinide and Alogliptin may significantly slow CIMT progression, improving cardiovascular risk management in patients with diabetes and/or cardiovascular disease. Further research is needed to understand the benefits and optimise oral hypoglycaemic treatment strategies for these patients."

Journal • Review • Atherosclerosis • Cardiovascular • Diabetes • Hypoglycemia • Inflammation • Metabolic Disorders • Type 1 Diabetes Mellitus

Identification of IL1R1 as a potential key PANoptosis-related gene in myocardial ischemia-reperfusion injury using machine learning. (PubMed, Sci Rep) - "Molecular docking suggested IL1R1 could be targeted by cardioprotective drugs such as Atorvastatin and Pioglitazone. This study suggests that IL1R1 may play a role in PANoptosis during myocardial ischemia-reperfusion injury. Based on bioinformatics, machine learning, and preliminary experimental validation, IL1R1 could be a potential biomarker or therapeutic target, although further research is needed to confirm its clinical significance."

Journal • Cardiovascular • Inflammation • Myocardial Ischemia • Reperfusion Injury • CD8 • IL1R1 • RELA

CT-L03-301: Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin (clinicaltrials.gov) - P3 | N=582 | Active, not recruiting | Sponsor: Celltrion | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Rational in silico design of PPARγ agonists for type 2 diabetes: an integrated study using pharmacophore modeling, 3D-QSAR, molecular docking, MD simulations, DFT, and toxicity prediction. (PubMed, Mol Divers) - "These compounds showed superior docking scores (- 10.919 to - 10.386 kcal/mol) and MM-GBSA energies (- 85.9 to - 63.96 kcal/mol) compared to the internal ligand SR145 (- 10.351 kcal/mol, - 85.63 kcal/mol) and standard drugs; rosiglitazone (- 7.272 kcal/mol, - 48.14 kcal/mol) and pioglitazone (- 7.033 kcal/mol, - 47.21 kcal/mol). Among the four identified hits, CHEMBL1825121 and CHEMBL4569907 were identified as the top candidates, displaying strong binding affinity, high structural stability and favorable pharmacokinetic properties. While experimental validation remains essential, these findings provide a rational strategy for the development of next-generation PPARγ modulators for T2DM."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Dissolution Profile of Ionizable Drugs in Biorelevant Bicarbonate Buffer at Intermediate Gastrointestinal pH Level. (PubMed, AAPS J) - "For the dissolution tests, febuxostat (FBX), dipyridamole (DPM), dantrolene Na (DNT Na), pioglitazone HCl (PIO HCl), and tosufloxacin tosylate monohydrate (TFLX TS) were employed. The dissolution profiles of ionizable drugs in BCB differed from those in CPB and ACB, especially in the case of the salt-form drugs with an acidic counterion. The floating lid method enables dissolution testing using BCB in the intermediate pH range."

Journal